Drug intelligence / Profile preview

PBK 1801

Development stage: Phase 1
Lead developer: Pharmbio Korea
Administration: Oral

Overview

PBK 1801 is an orally administered drug in clinical development by Pharmbio Korea. The specific disease indication and mechanism of action have not been disclosed publicly. Clinical trials for this compound are ongoing, but further details regarding its pharmacological class, molecular target, or therapeutic area have not been released[1].

Beyond the preview

Go deeper on PBK 1801.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PBK 1801.

Explore the full profile